-

BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2020

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com):

 

 

Six Months Ended
November 30,

 

Three Months Ended
November 30,

 

 

2019

 

2018

 

2019

 

2018

 

Revenue 

 

$

21,290,838

 

$

18,014,347

 

$

11,222,962

 

$

8,361,478

 

Income Before Income Tax 

 

$

3,132,524

 

$

1,698,986

 

$

1,258,041

 

$

811,813

 

Net Income 

 

$

2,216,324

 

$

1,201,986

 

$

891,841

 

$

574,313

 

Basic Earnings per Share of Common Stock 

 

$

2.48

 

$

1.35

 

$

1.00

 

$

.64

 

Diluted Earnings per Share of Common Stock 

 

$

2.48

 

$

1.35

 

$

1.00

 

$

.64

 

Weighted Average Number of Shares Outstanding For Basic Earnings Per Share

 

 893,416

 

 

 893,416

 

 

893,416

 

 

893,416

 

Weighted Average Number of Shares Outstanding For Diluted Earnings Per Share

 

 

893,838

 

 

893,579

 

 

893,838

 

 

893,579

For more detail related to the fiscal year 2020 unaudited second quarter results, please visit our web site at www.bioqual.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.

Contacts

Mark G. Lewis, Ph.D., CEO (240-404-7654)

BIOQUAL, Inc.

OTC Pink:BIOQ

Release Versions

Contacts

Mark G. Lewis, Ph.D., CEO (240-404-7654)

More News From BIOQUAL, Inc.

BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2026

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pink Limited): Three Months Ended August 31,   2025   2024   Revenue $ 9,855,399   $ 11,770,482     Loss Before Income Tax $ (343,432 ) $ (931,825 )   Net Loss $ (248,832 ) $ (675,325 )   Basic Earnings per Share of Common Stock $ (0.28 ) $ (0.76 )   Diluted Earnings per Share of Common Stock $ (0.28 ) $ (0.76 )   Weighted Average             Number of Shares Outstanding             For Basic Earnings Per Share   894,416     89...

BIOQUAL Presents Financial Results for Fiscal Year 2025

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets):     2025     2024   Revenue $ 48,867,753   $ 58,590,949   (Loss) Income Before Income Tax $ (1,896,010 ) $ 476,447   Net (Loss) Income $ (1,048,154 ) $ 483,481   Basic Earnings per Share of Common Stock $ (1.17 ) $ .54   Diluted Earnings per Share of Common Stock $ (1.17 ) $ .54   Weighted Average           Number of Shares Outstanding           For Basic Earnings Per Share   894,416     894,416   Weighted Average...

BIOQUAL Announces the retirement of Dr. Mark G. Lewis as President and CEO of the company

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets): Dr. Mark Lewis will be retiring as President of BIOQUAL effective May 31, 2025, and is succeeded by Dr. Hanne Andersen Elyard, BIOQUAL’s Chief Science Officer. Dr. Lewis will remain as Chairman of the Board of Directors. Dr. Lewis joined BIOQUAL as Senior Scientist in August 2003. He became the Executive Vice President in October 2008 and served in that capacity until he became President and CEO in 2010. “The entir...
Back to Newsroom